Study of 80,942 Tirzepatide Users Finds Women and Goal-Setters Lose More Weight
Updated
Updated · Healthline · Jun 17
Study of 80,942 Tirzepatide Users Finds Women and Goal-Setters Lose More Weight
3 articles · Updated · Healthline · Jun 17
Summary
80,942 new tirzepatide users were analyzed, and those who set baseline weight-loss goals or had tried diet plans lost a higher percentage of body weight over follow-up.
By 12 months, women were significantly more likely than men to reach 20% total body weight loss, while patients with pre-existing conditions were less likely to hit that threshold.
21,490 participants had six-month data and 4,429 had 12-month data, with most still accruing follow-up time in the study presented at ENDO 2026 in Chicago.
Researchers and outside clinicians said the findings support pairing GLP-1 drugs such as Zepbound and Mounjaro with realistic goals, diet, exercise and behavioral support to improve long-term results.